

Tobias Herold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6996572/publications.pdf>

Version: 2024-02-01

118
papers

5,576
citations

109321

35
h-index

88630

70
g-index

130
all docs

130
docs citations

130
times ranked

11137
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 1034-1044. | 3.5 | 4 |
| 2 | Differential impact of <i>IDH1</i> / <i>IDH2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405. | 5.2 | 17 |
| 3 | The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements. <i>Haematologica</i> , 2022, 107, 1758-1772. | 3.5 | 6 |
| 4 | Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients. <i>Journal of Hematology and Oncology</i> , 2022, 15, 25. | 17.0 | 1 |
| 5 | Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation. <i>Experimental Hematology</i> , 2022, 108, 26-35. | 0.4 | 1 |
| 6 | Streamlining preclinical in vivo treatment trials by multiplexing genetically labelled PDX models in a single mouse. <i>Klinische Padiatrie</i> , 2022, , . | 0.6 | 0 |
| 7 | HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. <i>American Journal of Hematology</i> , 2022, 97, 1200-1214. | 4.1 | 8 |
| 8 | TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. <i>Leukemia</i> , 2021, 35, 389-403. | 7.2 | 26 |
| 9 | Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 494-503. | 2.5 | 12 |
| 10 | Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. <i>European Respiratory Journal</i> , 2021, 58, 2002724. | 6.7 | 34 |
| 11 | Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML. <i>Scientific Reports</i> , 2021, 11, 5838. | 3.3 | 22 |
| 12 | MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF. <i>Cell Death and Differentiation</i> , 2021, 28, 3235-3250. | 11.2 | 9 |
| 13 | Fusion gene detection by RNA sequencing complements diagnostics of acute myeloid leukemia and identifies recurring NRIP1-MIR99AHG rearrangements. <i>Haematologica</i> , 2021, , . | 3.5 | 13 |
| 14 | In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. <i>Nature Communications</i> , 2021, 12, 5655. | 12.8 | 10 |
| 15 | A Clinically Applicable Gene Expression based Score predicts Resistance to Induction Treatment in Acute Myeloid Leukemia. <i>Blood Advances</i> , 2021, 5, 4752-4761. | 5.2 | 0 |
| 16 | An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 255-266. | 7.0 | 17 |
| 17 | COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454. | 7.2 | 57 |
| 18 | CSF3R T618I Collaborates with RUNX1-RUNX1T1 to Expand Human Haematopoietic Stem and Progenitor Cells. <i>Blood</i> , 2021, 138, 2233-2233. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia. <i>Blood</i> , 2021, 138, 708-708. | 1.4 | 0 |
| 20 | The clinical mutasome of core binding factor leukemia. <i>Leukemia</i> , 2020, 34, 1553-1562. | 7.2 | 60 |
| 21 | Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL. <i>Biomarker Research</i> , 2020, 8, 46. | 6.8 | 5 |
| 22 | Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 128-136.e4. | 2.9 | 783 |
| 23 | RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3597-3607. | 7.0 | 26 |
| 24 | COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363. | 7.2 | 198 |
| 25 | SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine. <i>Communications Biology</i> , 2020, 3, 324. | 4.4 | 23 |
| 26 | Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2621-2634. | 7.2 | 31 |
| 27 | Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 3161-3172. | 7.2 | 141 |
| 28 | Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 999-1012. | 3.5 | 19 |
| 29 | Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice. <i>Haematologica</i> , 2020, 105, 2855-2860. | 3.5 | 15 |
| 30 | The long non-coding RNA <i>Cancer Susceptibility 15</i> (<i>CASC15</i>) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e448-453. | 3.5 | 5 |
| 31 | Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49. | 1.4 | 2 |
| 32 | Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. <i>Leukemia</i> , 2019, 33, 64-74. | 7.2 | 212 |
| 33 | Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia. <i>Scientific Reports</i> , 2019, 9, 11796. | 3.3 | 9 |
| 34 | Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AML. <i>Journal of Hematology and Oncology</i> , 2019, 12, 72. | 17.0 | 12 |
| 35 | The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2830-2841. | 7.2 | 30 |
| 36 | Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. <i>Experimental Hematology and Oncology</i> , 2019, 8, 9. | 5.0 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The ParaHox gene Cdx4 induces acute erythroid leukemia in mice. <i>Blood Advances</i> , 2019, 3, 3729-3739. | 5.2 | 4 |
| 38 | PS929- Δ KLF4 EXERTS A TUMOR SUPPRESSOR FUNCTION IN PATIENTS' B-CELLS GROWING IN MICE AND IS UPREGULATED BY AZACYTIDIN. <i>HemaSphere</i> , 2019, 3, 418-419. | 2.7 | 0 |
| 39 | DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome. <i>Blood</i> , 2019, 134, 2715-2715. | 1.4 | 6 |
| 40 | PF210 CLINICAL ASPECTS AND DIFFERENTIAL SPLICING IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SRSF2, U2AF1 AND SF3B1 MUTATIONS. <i>HemaSphere</i> , 2019, 3, 57. | 2.7 | 0 |
| 41 | Gene Fusion Detection By RNA-Seq in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 4655-4655. | 1.4 | 0 |
| 42 | Identification of Recurrent Alternative RNA Splicing in Adverse-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 457-457. | 1.4 | 0 |
| 43 | Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity. <i>Blood</i> , 2019, 134, 1450-1450. | 1.4 | 0 |
| 44 | A CRISPR/Cas9 Library Screen in Patients' Leukemia Cells In Vivo. <i>Blood</i> , 2019, 134, 3945-3945. | 1.4 | 1 |
| 45 | Prospective Identification of Acute Myeloid Leukemia Patients Who Benefit from Gene-Expression Based Risk Stratification. <i>Blood</i> , 2019, 134, 1397-1397. | 1.4 | 0 |
| 46 | Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1598-1608. | 7.2 | 106 |
| 47 | A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 456-465. | 3.5 | 84 |
| 48 | Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients. <i>Clinical Cancer Research</i> , 2018, 24, 1716-1726. | 7.0 | 63 |
| 49 | A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. <i>Leukemia</i> , 2018, 32, 263-272. | 7.2 | 36 |
| 50 | Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data. <i>BMC Bioinformatics</i> , 2018, 19, 322. | 2.6 | 33 |
| 51 | Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA. <i>Blood Advances</i> , 2018, 2, 2724-2731. | 5.2 | 46 |
| 52 | Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia. <i>Scientific Reports</i> , 2018, 8, 11293. | 3.3 | 9 |
| 53 | Extracorporeal Membrane Oxygenation in Predominantly Leuco- and Thrombocytopenic Haematologic/Oncologic Patients with Acute Respiratory Distress Syndrome - a Single-Centre Experience. <i>Oncology Research and Treatment</i> , 2018, 41, 539-543. | 1.2 | 14 |
| 54 | Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. <i>Haematologica</i> , 2018, 103, 1853-1861. | 3.5 | 96 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | NPM1 Variant Allele Frequency and Outcomes in AML. <i>Blood</i> , 2018, 132, 1486-1486. | 1.4 | 6 |
| 56 | Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow – A proof of concept study. <i>PLoS ONE</i> , 2018, 13, e0193249. | 2.5 | 8 |
| 57 | Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 30128-30145. | 1.8 | 33 |
| 58 | Philadelphia-Like Acute Lymphoblastic Leukemia in Adults. <i>Current Oncology Reports</i> , 2017, 19, 31. | 4.0 | 25 |
| 59 | Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have <i>IGH-CRLF2</i> and <i>JAK2</i> mutations, persistence of minimal residual disease and poor prognosis. <i>Haematologica</i> , 2017, 102, 130-138. | 3.5 | 136 |
| 60 | Acute myeloid leukemia with del(9q) is characterized by frequent mutations of <i>NPM1</i> , <i>DNMT3A</i> , <i>WT1</i> and low expression of <i>TLE4</i> . <i>Genes Chromosomes and Cancer</i> , 2017, 56, 75-86. | 2.8 | 15 |
| 61 | Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. <i>Leukemia</i> , 2017, , . | 7.2 | 8 |
| 62 | RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. <i>Cancer Cell</i> , 2016, 30, 75-91. | 16.8 | 144 |
| 63 | Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 553-567. | 2.8 | 12 |
| 64 | IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. <i>Scientific Reports</i> , 2016, 5, 18411. | 3.3 | 51 |
| 65 | A 17-gene stemness score for rapid determination of risk in acute leukaemia. <i>Nature</i> , 2016, 540, 433-437. | 27.8 | 617 |
| 66 | Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. <i>Blood</i> , 2016, 128, 686-698. | 1.4 | 456 |
| 67 | Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL. <i>Journal of Hematology and Oncology</i> , 2016, 9, 95. | 17.0 | 23 |
| 68 | Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia. <i>Experimental Hematology</i> , 2016, 44, 1039-1043.e10. | 0.4 | 12 |
| 69 | GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. <i>Blood</i> , 2016, 127, 2018-2027. | 1.4 | 148 |
| 70 | ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. <i>Nature Communications</i> , 2016, 7, 11733. | 12.8 | 45 |
| 71 | miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. <i>Nature Communications</i> , 2016, 7, 11452. | 12.8 | 113 |
| 72 | Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. <i>Cancer Research</i> , 2016, 76, 4470-4480. | 0.9 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | A 4â€ gene expression score associated with high levels of <i>WT</i> expression is an adverse prognostic factor in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 401-411. | 2.5 | 14 |
| 74 | The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models. <i>Leukemia</i> , 2016, 30, 1166-1176. | 7.2 | 10 |
| 75 | PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1209-1209. | 1.4 | 1 |
| 76 | Normal B-Cell Gene Expression Signatures Classifies Chronic Lymphocytic Leukemia into Distinct Subtypes - Indication of Plasticity. <i>Blood</i> , 2016, 128, 2017-2017. | 1.4 | 0 |
| 77 | High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (â‰¥ 60 years). <i>Blood</i> , 2016, 128, 2840-2840. | 1.4 | 0 |
| 78 | RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. <i>Oncogenesis</i> , 2015, 4, e146-e146. | 4.9 | 16 |
| 79 | Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 679-684. | 2.4 | 21 |
| 80 | Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. <i>Leukemia Research</i> , 2015, 39, 779-785. | 0.8 | 43 |
| 81 | HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. <i>Lung Cancer</i> , 2015, 88, 34-41. | 2.0 | 17 |
| 82 | RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1505-1515. | 4.2 | 3 |
| 83 | Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 828-838. | 7.2 | 63 |
| 84 | Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. <i>Blood</i> , 2015, 126, 3784-3784. | 1.4 | 2 |
| 85 | DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCC) Trials. <i>Blood</i> , 2015, 126, 3815-3815. | 1.4 | 2 |
| 86 | Ph-like Acute Lymphoblastic Leukemia in Older Adults. <i>New England Journal of Medicine</i> , 2014, 371, 2235-2235. | 27.0 | 62 |
| 87 | Added predictive value of omics data: specific issues related to validation illustrated by two case studies. <i>BMC Medical Research Methodology</i> , 2014, 14, 117. | 3.1 | 6 |
| 88 | Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. <i>Blood</i> , 2014, 124, 1304-1311. | 1.4 | 81 |
| 89 | Ph-like acute lymphoblastic leukemia in older adults. <i>New England Journal of Medicine</i> , 2014, 371, 2235. | 27.0 | 30 |
| 90 | BCR-ABL1-like Acute Lymphoblastic Leukemia Is Associated with IKZF1 and JAK2 Alterations and inferior Outcome in Adults. <i>Blood</i> , 2014, 124, 3787-3787. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia. PLoS ONE, 2014, 9, e89560. | 2.5 | 60 |
| 92 | Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget, 2014, 5, 12371-12382. | 1.8 | 56 |
| 93 | Copy Number Alteration (CNA) Analysis in Targeted Sequencing Data from Acute Myeloid Leukemia (AML) Patients with Chromosome 9q Deletion. Blood, 2014, 124, 1058-1058. | 1.4 | 0 |
| 94 | Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution. Blood, 2014, 124, 697-697. | 1.4 | 0 |
| 95 | Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations. Blood, 2014, 124, 2385-2385. | 1.4 | 0 |
| 96 | Identification of TET1-Dependent miR-22-CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia. Blood, 2014, 124, 886-886. | 1.4 | 0 |
| 97 | The Mutatome of CFBF/MYH11-rearranged Acute Myeloid Leukemia (AML). Blood, 2014, 124, 14-14. | 1.4 | 1 |
| 98 | A 16-Genes Signature Associated with High Levels of Wilms Tumor-1 (WT1) Expression Is an Adverse Prognostic Factor in Acute Myeloid Leukemia. Blood, 2014, 124, 1021-1021. | 1.4 | 0 |
| 99 | Analysis of the Tissue-Specific Expression Requirements and Identification of Cooperating Mutations for Leukemogenesis in an Inducible CALM/AF10 Knock-in Mouse Model. Blood, 2014, 124, 126-126. | 1.4 | 0 |
| 100 | Integrative Analysis of LincRNA Expression and Clinical Annotations Reveals a Signature of 17 Genes with Prognostic Significance in Acute Myeloid Leukemia (AML). Blood, 2014, 124, 483-483. | 1.4 | 27 |
| 101 | Identification of a 24-Genes Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study. Journal of Clinical Oncology, 2013, 31, 1172-1181. | 1.6 | 164 |
| 102 | High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leukemia and Lymphoma, 2013, 54, 1652-1657. | 1.3 | 18 |
| 103 | Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. Blood, 2013, 122, 1761-1769. | 1.4 | 48 |
| 104 | Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis. Blood, 2013, 122, 608-608. | 1.4 | 5 |
| 105 | Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia. Blood, 2013, 122, 1312-1312. | 1.4 | 3 |
| 106 | Alterations Of The Chemokine Microenvironment In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 1619-1619. | 1.4 | 1 |
| 107 | RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica, 2012, 97, 1909-1915. | 3.5 | 82 |
| 108 | GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood, 2012, 120, 395-403. | 1.4 | 137 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 169-172. | 1.3 | 14 |
| 110 | Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia. <i>Blood</i> , 2012, 120, 404-404. | 1.4 | 3 |
| 111 | An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. <i>Leukemia</i> , 2011, 25, 1639-1645. | 7.2 | 59 |
| 112 | Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 1649-1652. | 7.2 | 57 |
| 113 | Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia—unexpected expression pattern of the RHO GTPase activator <i>ARHGAP20</i> . <i>Genes Chromosomes and Cancer</i> , 2011, 50, 546-558. | 2.8 | 16 |
| 114 | Role of Microenvironment-Associated Chemokines and Cytokines for Binet Stage A CLL Patients Included in a Prospective Trial (CLL1 trial) of the German CLL Study Group (GCLLSG): <i>si2Ralpha</i> Is An Independent Predictor of Progression-Free Survival (PFS). <i>Blood</i> , 2011, 118, 3869-3869. | 1.4 | 0 |
| 115 | High Expression of the Endoplasmic Reticulum Protein MZB1 predicts Inferior Prognosis in Chronic Lymphocytic Leukemia, Follicular Lymphoma and Diffuse Large B-Cell Lymphoma and Is Associated with a Unique Gene Expression Profile. <i>Blood</i> , 2011, 118, 3657-3657. | 1.4 | 16 |
| 116 | The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. <i>Leukemia</i> , 2009, 23, 649-655. | 7.2 | 38 |
| 117 | Breakthrough infection of <i>Trichosporon asahii</i> during posaconazole treatment in a patient with acute myeloid leukaemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 843-845. | 2.9 | 27 |
| 118 | Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. <i>Journal of Gene Medicine</i> , 2005, 7, 1429-1438. | 2.8 | 51 |